Revival Research Institute, LLC

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)16 trials
• Lupus (SLE)4 trials
• Alopecia areata3 trials
• Hidradenitis suppurativa1 trial
• Psoriasis1 trial
• Vitiligo1 trial

Phase

• Phase 213 trials
• Phase 38 trials
• Phase 2/32 trials
• Phase 42 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed11 trials
• Active, not recruiting7 trials
• Recruiting6 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• Pfizer8 trials
• Eli Lilly and Company4 trials
• EMD Serono Research & Development Institute, Inc.2 trials
• Hoffmann-La Roche2 trials
• Sun Pharmaceutical Industries Limited2 trials
• and 9 more

Running trials

• Recruiting

  A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

  NCT07840287· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

  Contact: Communication Center

• Recruiting

  A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

  NCT07783425· Phase 3· Pfizer· Source

• Recruiting

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  NCT07733765· Phase 3· Pfizer· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

  Contact: Ali Moiin (principal investigator)

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

  Contact: Ali Moiin (principal investigator)

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

  Contact: Communication Center

• Active, not recruiting

  A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

  NCT07223697· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Phase 2· Pfizer· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Barzolvolimab in Patients With Atopic Dermatitis

  NCT06727552· Phase 2· Celldex Therapeutics· Source

• Recruiting

  FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  NCT06564389· Phase 1· Pfizer· Source

• Active, not recruiting

  A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Phase 2· Pfizer· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alopecia areata2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Lupus (SLE)2 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

  NCT07150845· Phase 2· Evommune, Inc.· Source

• Completed

  A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

  NCT07006792· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Eli Lilly and Company· Source

• Completed

  Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

  NCT06144424· Phase 2· Escient Pharmaceuticals, Inc· Source

• Completed

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· Phase 1/2· Daiichi Sankyo· Source

• Terminated

  A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

  NCT05732454· Phase 2/3· Pfizer· Source

• Completed

  Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

  NCT05590585· Phase 4· Regeneron Pharmaceuticals· Source

• Terminated

  A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

  NCT05491447· Phase 2· BioMimetix JV, LLC· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

  NCT05469464· Phase 2· UNION therapeutics· Source

• Completed

  To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT04684485· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Completed

  To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

  NCT04566666· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source